论文部分内容阅读
ER测定用饱和分析法,凡乳腺原发瘤细胞溶质(Cytosol)中含4fmol以上雌二醇/毫克蛋白者定为ER(+),少于4fmol者为ER(-)。335例原发性乳腺癌中,177例ER(+)52.8%,158例ER(-)47.2%;手术后标本检查腋淋巴结有转移者为151例48.4%,未发现转移者为161例51.6%,余23例无病理报告可查。这些病人术后皆进行随访1～5年。结果按四个组分析,即:(1)ER(+)淋巴结(+),(2)ER(-)淋巴结(+),(3)ER(+)淋巴结(-),(4)ER(-)淋巴结(-)。 ER(+)比ER(-)病人术后无病生存期较长。尽管淋巴结有无转移仍为影响术后结果的决定性因素,但ER的存在显示某种保护作用,ER(+)者远比(-)者复发时刻推迟,而且即使肿瘤复发术后和死亡之间
The ER assay uses a saturation assay where ER (+) is defined as an excess of 4 fmol estradiol/mg protein in the cytosol cytosol (Cytosol) and less than 4 fmol is ER (-). Of the 335 cases of primary breast cancer, 177 were ER (+) 52.8%, and 158 were ER (-) 47.2%; post-surgical examination of axillary lymph node metastasis was 151 cases with 48.4%, and no metastasis was found with 161 cases 51.6 %, there were no pathological reports in 23 patients. All these patients were followed up for 1 to 5 years. The results were analyzed in four groups: (1) ER (+) lymph nodes (+), (2) ER (-) lymph nodes (+), (3) ER (+) lymph nodes (-), and (4) ER ( -) Lymph nodes (-). ER (+) patients have longer disease-free survival than ER (-) patients. Although the presence or absence of lymph node metastasis remains a determinant factor affecting postoperative outcomes, the presence of ER shows some protective effect. ER(+) patients are much more delayed than the recurrence of (-) and even between recurrence and death.